Announcement
Sativa Group PLC : Retail-major access through SHS Sales & Marketing
RNS Number : 5911R
Sativa Group PLC
30 October 2019
|
Press Release
|
30 October 2019
|
Sativa Group Plc
("Sativa" or "the Company" or "the Group")
Access gained to retail-majors through distribution agreement with
SHS Sales & Marketing (GB) Limited
Brand name change of George Botanicals to Goodbody Botanicals
Sativa Group Plc [NEX: SATI], the UK's leading quoted CBD wellness and medicinal cannabis Group, is pleased to announce that its wholly owned subsidiary, George Botanicals, has entered into a brand partnership agreement with SHS Sales & Marketing (GB) Limited ("SHS Sales & Marketing"). SHS will distribute a range of "Goodbody Botanical" branded products to UK high street grocery, pharmacy and specialist customers retailers.
SHS Sales & Marketing distributes over 100 blue chip Fast-Moving Consumer Good brands in the UK and Republic of Ireland including Mars, Colgate, Lemsip and Nurofen. SHS Sales & Marketing enjoys a market penetration to over 90% of UK households by distributing high quality products to the major high street retailers and leading convenience chains such as Sainsbury's, ASDA, Tesco, and Waitrose, as well as to pharmacies and health and wellness stores such as Holland & Barrett.
As part of the distribution agreement, SHS Sales & Marketing will market the Goodbody Botanicals range on an exclusive basis to its customer base, advising on product mix along with providing promotional and communications support. Logistics and invoicing are also included within the contract.
In tandem with this significant brand partnering agreement, George Botanicals is re-branding its highly successful George Botanicals product range to "Goodbody Botanicals". In this process the Goodbody Botanicals branding and packaging has been significantly upgraded, providing additional product information for customers. All products are tested and certified by Phytovista laboratories and are THC free.
Henry Lees-Buckley, Chief Executive of Sativa, said: "We are thrilled to be partnering with the highly regarded and successful team at SHS. The combination of their sales, marketing and logistics support, coupled with our high quality Goodbody products, make a compelling value proposition for major high street retailers".
John Heynen, Managing Director of SHS Sales & Marketing GB said: " The growing demand for CBD wellness products in the UK provides us with an opportunity to further extend our offer to our customers and shoppers, and it is critical we work with the best partner to realise this. All Goodbody Botanical products are rigorously tested to ensure that they bring high quality items to the marketplace. This attention to product development, quality and testing will provide our customers the sales opportunity and security they need".
For further information please contact:
|
Henry Lees-Buckley Chief Executive Officer Sativa Group Plc +44 (0) 20 7971 1255
|
Joseph Colliver Chief Financial Officer Sativa Group Plc +44 (0) 20 7971 1255
|
|
NEX Exchange Corporate Adviser
Corporate Finance
Stephen Keys / Max Gould Cenkos Securities plc +44 (0) 20 7397 8900
|
|
|
Equity Sales
Julian Morse Cenkos Securities +44 (0) 20 7397 8900
|
|
|
Financial PR and IR
Abchurch Communications Julian Bosdet +44 (0)207 4594 4070 +44 (0) 7771 663 886
|
|
Notes to Editors.
Sativa Group Plc is the UK's leading quoted CBD wellness and medicinal cannabis group with five operating subsidiaries.
Goodbody Botanicals provides CBD products online and to retail markets including pharmacies, wellness stores and grocers. Goodbody Wellness is a high-street retail brand with dedicated CBD wellness stores providing a premium shopping experience to consumers. Tessellate Collective is a direct-selling network marketing platform servicing consumers at home. Phytovista laboratories provides independent testing of CBD products to both external customers and fellow Group businesses.
Sativa Grow holds a Controlled Drug licence and cultivates cannabis plants to fulfil its partnership agreement with King's College London to research the impact of cannabinoids on inflammation and respiratory conditions.
- Ends -
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
NRAQBLBXKBFXFBB
;